Perspective Therapeutics Inc (CATX)
R&D Expense Growth
6.41%
Quarterly · Period ending:
CATX R&D Expense Growth
Latest reported6.41%period ending
Latest reported6.41%period ending
CATX Quarterly R&D Growth (QoQ) (0.00% → 6.41%)
Latest values, visible window
High-resolution chart · PNG
CATX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 6.4111% | |
| -38.5069% | |
| 61.8762% | |
| 67.0692% | |
| 7.1749% | |
| -11.8295% | |
| 7.1084% | |
| 61.4063% | |
| 39.2117% | |
| -11.9572% | |
| 7.5535% | |
| 5.27% | |
| 39.2274% | |
| 529.2007% | |
| -13.4181% | |
| -11.0553% | |
| 44.9909% | |
| 2.6168% | |
| -23.7892% | |
| 50% | |
| 29.2818% | |
| 27.0175% | |
| -8.6538% | |
| -3.1056% | |
| 9.5238% | |
| 6.1372% | |
| 18.8841% | |
| -31.6716% | |
| 14.0468% | |
| -27.7778% | |
| -1.4286% | |
| -26.5734% | |
| 20.9302% | |
| 39.1176% | |
| -6.0773% | |
| 14.557% | |
| -3.3639% | |
| 118% | |
| -12.7907% | |
| 20.5123% | |
| -22.0884% | |
| 214.5651% | |
| -59.5318% | |
| -7.8342% | |
| 10.4216% | |
| 0.549% | |
| -20.3743% | |
| -10.8804% | |
| 29.009% | |
| -9.6565% | |
| 15.6745% | |
| -18.9343% | |
| 16.8786% | |
| 3.996% | |
| 5.4456% | |
| -31.777% | |
| 56.8147% | |
| -30.2772% | |
| -5.7885% | |
| -32.2091% | |
| 57.9036% | |
| 1,104.6246% | |
| -86.3677% | |
| 0.4271% | |
| 15.2288% | |
| 67.5141% | |
| -14.233% | |
| -47.8767% | |
| -56.2276% | |
| -1.3556% | |
| 40.0394% | |
| -19.5744% | |
| -37.4469% | |
| 9.8277% | |
| 54.2868% | |
| -42.5396% | |
| 2.0645% | |
| 102.1433% | |
| -11.948% | |
| 1.6498% | |
| 180.3119% | |
| -10.9906% | |
| 275.5993% | |
| 0% | |
| -67.7725% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |